In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors
about
Unique Thermodynamic Response of Tipranavir to Human Immunodeficiency Virus Type 1 Protease Drug Resistance MutationsHIV vulnerability of men who have sex with men in developing countries: Horizons studies, 2001-2008.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.Club drugs as causal risk factors for HIV acquisition among men who have sex with men: a review.New anti-HIV agents and targets.Early factors in successful anti-HIV treatment.How Many HIV infections may be averted by targeting primary infection in men who have sex with men? Quantification of changes in transmission-risk behavior, using an individual-based model.Surveillance of HIV risk and prevention behaviors of men who have sex with men--a national application of venue-based, time-space sampling.The contribution of antenatal care to the coverage and correlates of HIV testing among adults in Zimbabwe 2005-06.Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies.Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.Tipranavir: a protease inhibitor for HIV salvage therapy.Sexual orientation disparities in sexually transmitted infections: examining the intersection between sexual identity and sexual behavior.Review of tipranavir in the treatment of drug-resistant HIV.P-glycoprotein related drug interactions: clinical importance and a consideration of disease states.Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.Sexual health, HIV, and sexually transmitted infections among gay, bisexual, and other men who have sex with men in the United States.Ritonavir-boosted protease inhibitors in HIV therapy.Sexually transmitted diseases and human immunodeficiency virus-discordant partnerships among men who have sex with men.Tipranavir in the protease inhibitors arena.Beyond prevention: containment rhetoric in the case of bug chasing.Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.Sexual behavior among HIV-positive men who have sex with men: what's in a label?Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.Male injecting drug users in the Deep South: bisexual behaviour is a marker for elevated HIV risk.Sociocultural facilitators and barriers to condom use during anal sex among men who have sex with men in Guangzhou, China: an ethnographic study.Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats.The relationship between socioeconomic factors, wellbeing, and homosexuality in the theatrical profession.The impact of male-to-male sexual experience on risk profiles of blood donors."Barebacking": intentional condomless anal sex in HIV-risk contexts. Reasons for and against it.Long-term HIV/AIDS-related prevention behaviours among men having sex with men: Switzerland 1992–2000Tipranavir: a novel protease inhibitor for HIV therapy
P2860
Q27644072-75A74F3B-CE72-4F34-96B9-234B077C3E99Q33652809-7D4270AC-8B74-4B6E-BBAD-1BF967D1CD02Q33906239-562B3B43-D849-4423-8266-513C51654C5BQ34228277-8405BA84-69B3-4DC0-A872-3817688AFAE8Q34569081-0EC8C7B2-444F-4BA5-93F1-8BB688B57B83Q34944447-8BBAD8EC-422A-49C9-A653-1D6FD9911CB1Q35207282-10436F80-84E8-41FF-BC20-0FA64E4FD360Q35233792-D906AFED-7455-4AD1-971F-EC2A7CFF8425Q35648749-6EAEB2B0-1886-43CF-B5BB-111C56612BBCQ36175347-020189BB-B7F4-4694-BD75-DEA51B234C21Q36375914-3B5F75ED-7BBF-4E48-9DB5-D26B7C7A145EQ36414526-3D1F29C8-99D6-409A-B1E5-AAFDDF8A9783Q36482890-5D5A111E-E9DA-4307-AB09-6C83D8E46D09Q36513619-4C180F60-7A84-4A96-94F6-82808FA092CDQ36617831-FBD6F44C-DFC4-418A-9EBC-B50250B38A4EQ36642990-F4049D6C-11FC-49DD-A6FE-8274D280A9E7Q37732337-A0584E25-75F9-4EFB-A465-114E6AE7466AQ37823558-80B8FB4E-0578-426F-BB9E-9D6D0BAD912CQ37844494-623C0F83-5B57-4847-8D37-D6C5DFF6991AQ37866319-50755A7D-5BEC-4C3F-A536-E4D903CEF07EQ37871144-8C69DB13-890C-4DE8-9BE9-A12CB97278D8Q37963591-A08A64C0-F8E4-4957-B5CF-370072EA6606Q38200535-35506D60-1B79-484E-A910-9CCDD6DF3D12Q39290078-81F11EF2-7713-4D97-B143-C122C8580233Q39657212-E221A14D-151E-48EB-A423-7163482426CDQ42003165-1E7FFA66-C774-4069-B8A6-70C0B64F2AA7Q43608992-F46BBCA3-833B-4655-A07C-78C893183B5CQ44747816-C72FBCDB-5020-4940-BAC6-5D26E50F0BBDQ45245263-27A95005-172C-4637-8FE9-16A7634672EEQ46990276-ECE1708C-F791-4EED-866D-571480F029DDQ48365605-E9504FC7-8976-4DFB-931B-586B4D5E2605Q50134674-2EB50151-4ACC-4462-8280-F4E975B2C449Q51663789-09A407A1-2BE9-49D7-8A69-954CA37BE3E2Q58280433-70AD9AF1-9041-4A1F-B982-F77704CE54EBQ58388976-151FE8AF-25F0-43C9-B4A1-B48265652406
P2860
In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In-vitro tipranavir susceptibi ...... y to other protease inhibitors
@ast
In-vitro tipranavir susceptibi ...... y to other protease inhibitors
@en
In-vitro tipranavir susceptibi ...... y to other protease inhibitors
@nl
type
label
In-vitro tipranavir susceptibi ...... y to other protease inhibitors
@ast
In-vitro tipranavir susceptibi ...... y to other protease inhibitors
@en
In-vitro tipranavir susceptibi ...... y to other protease inhibitors
@nl
prefLabel
In-vitro tipranavir susceptibi ...... y to other protease inhibitors
@ast
In-vitro tipranavir susceptibi ...... y to other protease inhibitors
@en
In-vitro tipranavir susceptibi ...... y to other protease inhibitors
@nl
P2093
P1433
P1476
In-vitro tipranavir susceptibi ...... y to other protease inhibitors
@en
P2093
A van Wijk
C A Boucher
D Remmerswaal
M van Monfort
R Schuurman
P356
10.1097/00002030-200001070-00019
P407
P577
2000-01-07T00:00:00Z